Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

The combination of nivolumab and ipilimumab in patients with metastatic colorectal cancer led to 24-month progression-free survival of 72%, as compared with 14% with chemotherapy.

​   The New England Journal of Medicine: Search Results in Hematology/Oncology